ELV changes
Pick any two versions below to diff them.
- Price
- $420.07 → $429.48(+2.2%)
- Recent events
- added: Nov 10, 2026: Elevance Health said that its officers will reaffirm the 2026 guidance in meetings with investors: diluted EPS of at least $22.00, adjusted diluted EPS of at least $29.00 and a benefit expense ratio of 90.2%, plus or minus 0.5 percentage points. Oct 21, 2026: Elevance Health reported Q3 2026 results. Operating revenue rose 0.7% to $50.4 billion, GAAP diluted EPS was $6.27 and adjusted diluted EPS was $6.99. The benefit expense ratio improved 70 basis points to 90.6%, and Carelon operating gain rose 17%. Medical membership fell by 487,000 from a year earlier to about 44.9 million. Elevance raised its 2026 guidance to at least $29.00 of adjusted diluted EPS and at least $6.5 billion of operating cash flow. It expects at least 12% growth in adjusted diluted EPS in 2027 from a 2026 baseline of at least $26.75. Oct 21, 2026: In its Q3 2026 quarterly report, Elevance said that its 2027 Star Ratings, which CMS released in October 2026, put about 49% of its current Medicare Advantage members in plans with 4 stars or more. Its 2026 Star Ratings put about 55% of members in such plans. The 2027 Star Ratings set the Medicare Advantage bonus payments for 2028. Jul 15, 2026: Elevance Health reported Q2 2026 results. Adjusted diluted EPS was $7.45, and the company raised its 2026 adjusted EPS guidance to at least $27.00. It said that it will speed up targeted investments in medical cost management, member experience, provider connectivity and Carelon. Jul 13, 2026: CMS told Elevance in a letter that the company had completed all required steps in the Medicare Advantage risk adjustment matter. CMS did not impose sanctions and closed the enforcement process. Apr 22, 2026: Elevance Health reported Q1 2026 results and raised its 2026 adjusted EPS guidance to at least $26.75. Adjusted diluted EPS was $12.58. The company recorded $935 million for its best estimate of the potential exposure on historical Medicare Advantage risk adjustment data linked to the CMS notice. Mar 2, 2026: Elevance said that CMS notified it on February 27, 2026 of a plan to suspend new enrollment into its Medicare Advantage prescription drug plans from March 31, 2026. CMS said that the matter concerns risk adjustment data for dates of service before April 3, 2023. The benefits of current members did not change. Feb 26, 2026: Elevance announced management changes. Chief Financial Officer Mark Kaye also took responsibility for Carelon, and Felicia Norwood took responsibility for all Health Benefits businesses. Carelon President Peter Haytaian left that role on May 4, 2026. Jan 28, 2026: Elevance Health reported 2025 results. Adjusted diluted EPS was $30.29 for 2025, and the company guided 2026 adjusted diluted EPS of at least $25.50.